share_log

HC Wainwright & Co. Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $83

HC Wainwright & Co. Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $83

HC Wainwright & Co. 維持對Apellis Pharmaceuticals的買入評級,將目標價下調至83美元
Benzinga ·  08/02 17:21  · 評級/大行評級

HC Wainwright & Co. analyst Douglas Tsao maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and lowers the price target from $92 to $83.

HC Wainwright & Co. 分析師Douglas Tsao 維持apellis pharmaceuticals(納斯達克: APLS)的買入評級,將目標價從92美元降至83美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論